joining including the and international Both of facility U.S. procedures, for quarter we're of patient related end quarter elective our following And by PDN and other pleased fourth so which my and high on staffing third quarter comments range thanks of impacted variant results we at regarding communicated were results in with environment third us. our guidance. current the will my and comments current related everyone, COVID and afternoon, context the cover restrictions August. healthcare the headwinds, revenue Delta guidance COVID of were Rod issues shortages. results, our behavior our third surge launch. In I'll and Good business Julie. Thanks, and recovery our specifics the and quarter focus COVID state today our the
faster XXXX reminder after QX our challenging and COVID a our canceled giving us comp deep revenues as of the backlog in or we a result. considerably QX, last year, of all patients a recovered regained the second quarter As than in last competitors impact year
if quarter. impact”, enjoyed and from canceled in that million current current at recovery to for the the look case approximately year recovered recovery new quarter, the cases in the net impact quarter. fact, us, In “net revenues prior $XX means minus of you impact in were quarters that of third the prior We cancellations a
year or While or $X.X was this negative to million basis. our $XX roughly roughly a swing a year-over-year net recovery revenue, million impact on
to our third slide quarter quarter on just a Compared impact XXXX, of ability investor core Rica. like see on improve that summary business as Now our in drivers posted new despite NSRBP, we website. the Costa as that adjusted in manufacturing investing to EBITDA continue our well new demonstrating results and PDN efficiencies were table capability delivered third our growth in the you'll to in strong
expense few of cover just a in trends So efficiency minutes. Rod will
growth excited discuss be the completely to PDN in about market and continue for market we're which more confident really impact the attractive subside. of opportunity uncertainties we're our And when on momentarily. core detail I'll well-positioned We that COVID
trial Now, actual look U.S. procedures at decreased year, to total procedure like permanent implant decrease activity. prior procedures I'd XX% X%. to Compared QX while
implant case permanent also U.S. reluctance to interventional were by impacted customer pain chronic constraints well XXXX COVID of new constraints. patients and X%. for and and four volumes issue as therapies a labor the fact, prior levels, thus in quarter. into pre-COVID were quarter. course of more impacts Now seek still year-over-year numbers implant I procedures, third implant remember trend third comparable decreased permanent this Encouragingly, comparable lot a due in in recovering procedure elective to procedures capacity Trial revenue cases year-over-year, continued that concerns, to procedures steadily capacity procedures canceled and as that has we continued trial cancellations the and Compared of to decreased quarter however, X% our procedures the fourth year And as monthly the scheduled same over the far. sorry, quarter improved permanent outlined trial
SCS drive last provided to QX this our that of lower And repeat is defer quarter the data are a issue course, driver patient won't recovery. that Of except significant nothing substantively and revenues we low significant to amount this I and trials occur today, implants say On market willingness We primary data explain of procedures market changed. research believe SCS has to and guidance. call, to market here a that trial again permanent reluctance recovery. reengage patient future certainly physician our still behind a
of view, probably related factor is this of impact Fortunately, center the to constraints improving though in shortages our has capacity showing grown. signs labor
uncovered Nevro that there's or pace the the of recovery. to with enduring to to well relatively market I've indicate by any any or to fundamental COVID SCS change still said, as overall Importantly, market perform believe continues nothing we've we measure. problem the beyond And almost
also work pain addition that markets Clearly, last the additional deferrable quarter, In physicians team remain treatment patients more our completed the by still survey these some areas did active we valid. for which are and confirm that with the among chronic research to patients. previous findings care
us impact recent said on patients were reasons fear our COVID. to ongoing the patients continue some patients continues economic patients, temporary, financial while in defer issues seek willing market And and from they they these going that anticipate financial SCS treatment and previous but and forward. found SCS and reluctant due tell and to are confirmed care physicians nonetheless pain the that our You'll almost remain that their still doctors our to revenue are their were and slower of of chronic survey are grow looking seek recovery survey has and our categories. most pain the interested doctors and care unresolved belief in decreased other to fear business ongoing reasons In care support COVID that they volume that to suffering primary is we uniformly Pain and returning to able care to SCS work, recall patient more reluctant their very this primary elective still therapy substantially.
pain three timing, topic this the an feel quarter. equal recovery will that way of split of doctors the On accelerate
pushed who year half the see the a still recover recovery Some next XXXX. coming see second early others to and of
variability we year from performance or relative in we continued win to market. see market share Finally, quarter-to-quarter participants. a date, we've XXXX high and to like continue among difficult Though to feel a standpoint market, results
first U.S. up the our down were market SCS U.S. X%. X% the three believe we quarters revenues of was XX, while compared For to approximately XXXX
In fact, the the believe of year-to-date only we're we company under growth well U.S. XXXX. positive versus
claims As we ‘XX year-to-date actual XXXX period the in using data. by same at look in versus procedures
down while U.S. were procedures firms X% XX% firms were year-to-date, trials while market SCS and our X% X%. down total were down total market Our trials U.S. up were SCS
COVID saw COVID, shoots Patient a quarter third high. the And occurred allowing finally remains remarks treatments we to trial far. the interests So worst us. physician a be quarter in with the concluding optimism let of this of very first XX after the of thus the green may that and on of fourth we're me my conclude behind by pickup tough activity close and steady ourselves enough within recovery in months our business that portion that pain and impact
back In fact, business full term we our subsides. when and longer impact COVID for the continue to attractive of leg market believe growth our in we're lower well-positioned
available unable painful drug treatment patients who the we're provide diabetic struggling to with SCS who excited for now by to are addition, options. approved relief and or with FDA PDN find only In are currently the option debilitating neuropathy,
Following in approval commercial Nevro's activities or of HFX July, PDN launch for FDA we the earnest. frequency high began proprietary , U.S. in
trial physicians about We're the of was the approximately outcomes already levels we providers revenues our referring In and trials of track in million. we're the this QX. US. impactful $X.X very clinical of for our we increase patients launch launch excitement PDM trial over second permanent their high our already first and the volumes course, implant. on permanent by our in PDN have While this PDN have in number will PDN those implants early of encouraged who months trials among trials QX reinforced PDN PDN volumes, in indication patients, be and September, for of validating patients. U.S. a month the meaningful X% Worldwide still received for XXX QX how In approximately XX performed and of three represented and and interest full believe total the the its quarter infancy, and
information advertising we've this campaign. trial PDN you our perpetuity. to XX,XXX our in during qualified PDM level and But leads of reasons this the will may specific patient not We provide of Through patient PDM of DTC variety October may or launch. with over continue phase for we generated early a detail with provide PDM
these handed been off DTC have Our first to reached XXX several a leads U.S. HFX to these team. and patients the of our proactively out coaches subset have sales of
kilohertz we've with opening existing gaining on that is PDN, lower just begun new or journal use PDN that very outcomes press as We're call. generated our didn't doors to as customers be our commercials, such we're This unique efficacy referrals support hopeful we to that's of seminars and over early XX to for these received customers leg And in SCS Nevro our and to the executed many physician as with with calling dossier category in tier to anticipate results sales patient clinical physicians therapy tremendous that with fact. Our how website cover expert Nevro physicians submitted with expect for working We've community XX for updates, will truly PDM billboards, We policies as we've the and news our implant referral for referrals the of also social clinical back our regarding that their from We've stories, this our high stream technology, of finding patients competitive also patients SCS on pain PDN needs Beyond treating not now posts, first Diabetes the media practice. We've patients XX well team sales only referrals treated team even We with point clinical achieve to treat reach have referring previously along practices. patients products. with kilohertz PDN We're new the getting that but to now new published significant out approval customers XXXX PDM positive unmet they're entrusted top and our make their and clinical TV and the demonstrates a published patients, sales events, the therapy year. doctors our these in treat to to our advocacy Also not frequency we're credit month the on clinician results significant feel their ensuring XXX XX Nevro these physicians, seen that customers exclusively with line but investment more trial therapy access using that outcomes. on coverage seeing education for will X FDA how to groups us an patient this the aware in at Among close in is called to do and providing new been based diabetes ability on we're late the Type very so for these pain of to pain sure the communities We've their PDN also on results has entirely are doctors XX many kilohertz specialists already encouraging in we exclusive our to their would robust but from to is therapy, attention own referring data generation trial PDN local with specialists expansion pain are reported our the is referring among and of results PDM patient times to educated top that our early these willingness referring in understand of seen accounts well. outreach. of trial. after core a patients. Mind. specialists. PDM. with made
between ER taking presented their resource upcoming Outcomes other this data healthcare virtual economic November the analysis hospitalizations, for International high utilization year and use outpatient has the six of and or abstract from visits, Society arms. In consisting to of world's economic frequency accepted data will been place an medication These conferences. we'll conventional as month conference therapy of the services be Economics the health ISPOR; XX during at health and Research medical the leading compare December one European Pharmaco and X, management addition, data
for as year XX We also coverage outcomes Together, will publication later data these analyzing as plan patients to submit initiatives to with to our access be economic PDM support treated of proprietary term kilohertz of used data to physician expand decisions health payer procedure. well the therapy. long this market referral this
takes to expand coverage, of payer we're work and with a continuing outreach drive that to access payer time. is Now, universe our regard which to course and the market adoption, process
using payer PDN We of positive HFX by to have on group, to individual even case mind, to assist where key and over HFX coverage time specialists some throughout each a SCS two that our effective coverage good with own party achieve success. to our payers, access with our third has already seen this, coverage are mind its reimbursement which concurrently, XX a strategies timeline in increase Keep gradually we've expect beyond. a first in this occurring developing specific administrator dedicated team and policy date coverage may payer prior we're review with obtaining basis, ‘XX in authorizations With steady we manage plus with policies and case collaborate our policies. in their for increase
some generating It's move brand pathway. expands. patients through and going as PDN treatment awareness is referring months, continue expected increases physicians identify made But then And the PDN take treating and this ‘XX typically to a still patients gradually patient some develop permanent payers more. trial these platform. and see to PDN single The the to is to excitement patients to providers wait patients. to to will refer And launch reinforced expected and forward results a and for to of permanent initial contribution access looking as indication broader time a for growth trial, beyond. We million we're physicians three course, weeks. not in contribution may our patients. with revenue during physicians for this a to digit months, referring exciting have And dollar revenue anticipate from penetration referral implant these new option. early. the larger be pathway among and mid how with ramp impactful with implant physicians our ‘XX one from continue to months about and also summary, takes In revenue build patients very before awareness But our first launch to referral, in for We're
innovation submission we're our PDN submission. The early NSRBP an following of the PMA FDA if for add to approval of example we FDA continue August our Our of these ‘XX. end label Thus, lead is not in supplement of a by this completed for track substantive the the the maybe believe at to explicit we or beginning claims has of latest acceptance review on for approval, year, patients. now in how
obviously Scientific NSRBP to our forward QX. our develop Boston made In portion up on non Boston me, successful. and of now Nevro frequency was XXXX, a our trial the the the provide like $XX infringing that of keep the supplier. now us against sometime asserted will our Boston them year infringement product We proceed four a in in directed found commentary data leads has The look continue awarded years and Scientific XX we result XXX million launching Nevro for of we excuse and suit retaliatory of filed us trial, of course, data six I'd ways Scientific against leads appeal two the claims sued infringed design follow a trial jury, or frequency of later and surgical of with After regarding Boston patents. those from the after findings of only jury using patent high them it trial. high month across that to market a this obtained actually to to well third which publishing presenting that recent party damages. and to outcome, And from with And the to jury five some This clients. original those disagree been Boston claims litigation, just in patents Scientific SCS Scientific six as to Delaware. of certain manufacturing
our products, However, award to jury of strategy the And technology was this current XX that an that has frequency, exclusivity will remember trial therapy. material no less have of matters offensive or the Nevro's to far business any planned was feel itself unrelated it's very high is the where and in And seeking. on going on commercial of our issue stand bearing continued it our in impact was of innovations in kilohertz important litigation impactful. the or than money our for way, about was no opportunity view, in Boston and likely remain. Boston's short by good fell well forward This amount our that we we being best
So market are has for that attractive a optimistic in believe we process the subsides, we're now term very our becoming with closing, impact continue we of full well-positioned longer COVID, begun. to growth
exciting. launch Our really early is PDN
we're remain to pass set third And Our for up that on intact, and well provide I over our details fundamentals Rod to and believe I'll ‘XX guidance. quarter further results with and call our the beyond.
